USA

Under the agreement, Lilly will obtain exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialise sonefpeglutide, a long-acting GLP-2 analogue.

The regulatory decision follows results from a Phase Ib study presented at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference and the 2026 International Scientific Congress on SMA Europe.

Under the agreement, Servier will take control of Edgewise Therapeutics’ muscular dystrophy portfolio, including its lead candidate sevasemten.

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

Through this arrangement, Pfizer aims to accelerate the identification and design of new therapeutic candidates, particularly in areas where traditional research methods have faced limitations.

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The Bundibugyo strain remains particularly challenging because no approved vaccine or specific treatment is currently available.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

The decision expands Imfinzi’s bladder cancer footprint beyond its earlier approval in muscle-invasive bladder cancer (MIBC), where it is used with chemotherapy agents’ gemcitabine and cisplatin before surgery and as a monotherapy afterward.

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.